IND
ENG
A major initiative to elevate Indonesia’s national research capabilities was completed on October 13, 2025, with a comprehensive site assessment at RS Penyakit Infeksi (RSPI) Prof. Dr. Sulianti Saroso (Sulianti Saroso Infectious Disease Hospital) in Jakarta.
This strategic assessment was driven by a collaboration between the Indonesia Clinical Research Center/ INA-CRC (https://ina-crc.kemkes.go.id/) and IASMED.
Defining the Core Research Capacity
Given its national mandate as the reference center for infectious diseases, the assessment at RSPI Sulianti Saroso was highly focused. Its goal was to produce an initial assessment report detailing the current state of the hospital’s Clinical Research Unit (CRU) capacity, specifically in the context of infectious disease clinical trials (e.g., emerging and re-emerging infectious diseases).
The report will provide crucial data points—from infrastructure and specialist resources to regulatory compliance—needed to accurately define the hospital’s readiness for large-scale, complex trials.
Ms. Indri Rooslamiati, head of INA-CRC stated,”These recent site assessments mark a critical milestone in our goal to build a robust and internationally competitive clinical trial ecosystem.“
The Next Phase: Global Trial Readiness
The completed assessment report will immediately inform a strategic development plan. This plan is designed to implement necessary improvements, including improvement of standardized system, targeted training and global promotion.
The successful implementation of this plan will significantly increase site visibility to international Sponsors and Contract Research Organizations (CROs), enabling RSPI Sulianti Saroso to attract cutting-edge clinical trials and accelerate the development of new treatments and vaccines for both local and global health threats.